drugset
drugset / Trial / NCT07492303

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

NCT07492303 ↗

Phase 1 Not yet recruiting 96 enrolled Changchun BCHT Biotechnology Co.
RandomizedParallel-groupSingle-blindPrevention

Summary

the safety and tolerability of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine

Timeline

Start
2026-04-20
Primary completion
2026-07-10
Completion
2027-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Adacel Vaccine — Intramuscular

Indications

diphtheria pertussis tetanus